Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Warrant (NQ:ASBPW)

0.0297 +0.0066 (+28.57%)
Streaming Delayed Price Updated: 3:50 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aspire Biopharma Holdings, Inc. - Warrant

< Previous 1 2 Next >
News headline image
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
Via ACCESS Newswire
News headline image
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
Via ACCESS Newswire
News headline image
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Provides Q3 2025 Business Update
Via ACCESS Newswire
News headline image
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Via ACCESS Newswire
News headline image
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
Via ACCESS Newswire
News headline image
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
Via ACCESS Newswire
News headline image
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
Via ACCESS Newswire
News headline image
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20
Via ACCESS Newswire
News headline image
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc. Announces CEO Transition
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.